ACC.18

The ANCHOR study was not designed to determine effects on hsCRP or CV events.

Some FH patients may have suboptimal LCL-C despite treatment with PCSK9 inhibitors, statins and ezetimibe.

The new analysis focuses on the remaining 4,960 patients, who had prediabetes at the start of the trial.

Cocaine and/or marijuana use present in 10.7% of myocardial infarction patients age ≤50 years

Magnetically levitated centrifugal-flow pump beats mechanical bearing axial-flow pump at two years

The primary efficacy outcome was the combined rate of death from a cardiovascular cause, heart attack, stroke due to inadequate blood supply, blood clots or amputation due to cardiovascular disease.

The trial enrolled 105 patients who had HFpEF causing shortness of breath and fatigue with ordinary or mild physical activity.

ANNEXA-4 is a global, single-arm, open-label clinical trial designed to evaluate andexanet alfa in patients who present with an acute major bleed while receiving apixaban, rivaroxaban, edoxaban or enoxaparin.

The study recruited 319 men at 52 Los Angeles County barbershops.

The ODYSSEY Outcomes trial (N=18,924) evaluated the effect of alirocumab on the occurrence of MACE in patients who had an ACS between 1-12 months prior to trial enrollment, and who were already taking maximally-tolerated statins (atorvastatin or rosuvastatin).